Enhanced immunogenicity of an HIV gag peptide by conjugation to MHCIIβ2 or IL-1β epitopes is augmented, with type 1 T-cell responses, by FLT3 ligand.

被引：0
|
作者：
Pisarev, VM
Parajuli, P
Mosley, RL
Sublet, J
Zimmerman, D
Sarin, P
Winship, MD
Talmadge, JE
机构：
[1] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Transplantat Immunol Lab, Omaha, NE 68198 USA
[2] Cell Sci Corp, Vienna, VA 22182 USA
来源：
FASEB JOURNAL | 2000年 / 14卷 / 06期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：A943 / A943
页数：1
相关论文
共 43 条
  • [1] Flt3 ligand and conjugation to IL-1β peptide as adjuvants for a type 1, T-cell response to an HIV p17 gag vaccine
    Pisarev, VM
    Parajuli, P
    Mosley, RL
    Chavez, J
    Zimmerman, D
    Winship, D
    Talmadge, JE
    VACCINE, 2002, 20 (17-18) : 2358 - 2368
  • [2] Flt3 ligand enhances the immunogenicity of a gag-based HIV-1 vaccine
    Pisarev, VM
    Parajuli, P
    Mosley, RL
    Sublet, J
    Kelsey, L
    Sarin, PS
    Zimmerman, DH
    Winship, MD
    Talmadge, JE
    INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, 2000, 22 (11): : 865 - 876
  • [3] FLT3 ligand (Flt3L) and IL-1β bioactive fragment, T cell specific adjuvants for peptide vaccines.
    Pisarev, VM
    Parajuli, P
    Kelsey, L
    Mosley, RL
    Sarin, P
    Zimmerman, D
    Winship, D
    Talmadge, JE
    FASEB JOURNAL, 1999, 13 (05): : A847 - A847
  • [4] Intramuscular (IM) injection of Flt3 ligand (FL) plasmid formulated with a pluronic carrier results in recruitment of dendritic cells (DC) and augmented T cell responses to an HIV-1 gag DNA vaccine
    Pisarev, VM
    Sang, HX
    Chavez, J
    Robinson, SN
    Talmadge, JE
    FASEB JOURNAL, 2002, 16 (05): : A1038 - A1038
  • [5] Flt3 ligand augmentation of T cell mitogenesis and expansion of type 1 effector/memory T cells
    Mosley, RL
    Parajuli, P
    Pisarev, V
    Chavez, J
    Meeks, A
    Steffel, A
    Leutzinger, C
    Talmadge, JE
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2002, 2 (07) : 925 - 940
  • [6] A comparison of standard immunogenicity assays for monitoring HIV type 1 gag-specific T cell responses in ad5 HIV type 1 gag vaccinated human subjects
    Tobery, Timothy W.
    Dubey, Sheri A.
    Anderson, Kiersten
    Freed, Daniel C.
    Cox, Kara S.
    Lin, Jing
    Prokop, Michael T.
    Sykes, Kara J.
    Mogg, Robin
    Mehrotra, Devan V.
    Fu, Tong-Ming
    Casimiro, Danilo R.
    Shiver, John W.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2006, 22 (11) : 1081 - 1090
  • [7] Induction of type 1T cell response by administration of p53/adenovirus and p53/nDNA vaccine with Flt3 ligand.
    Parajuli, P
    Pisarev, V
    Laface, D
    Sublet, J
    Talmadge, JE
    BLOOD, 1999, 94 (10) : 419B - 419B
  • [8] Administration of a wild-type p53 genetic vaccine with Flt3 ligand induces a tumor-specific type 1 T-cell response
    Parajuli, P
    Pisarev, V
    Laface, D
    Sublet, J
    Talmadge, JE
    CANCER GENE THERAPY, 1999, 6 (06) : S26 - S27
  • [9] Improvement of the immunogenicity of a HIV-1 clade C candidate vaccine increasing Gag, Pol, Nef and Env specific T-cell responses
    Wild, J.
    Koestler, J.
    Bredl, S.
    Boeckl, K.
    Wagner, R.
    WIENER KLINISCHE WOCHENSCHRIFT, 2008, 120 : 17 - 17
  • [10] Immunization with wild-type p53 gene sequences coadministered with Flt3 ligand induces an antigen-specific type 1 T-cell response
    Parajuli, P
    Pisarev, V
    Sublet, J
    Steffel, A
    Varney, M
    Singh, R
    LaFace, D
    Talmadge, JE
    CANCER RESEARCH, 2001, 61 (22) : 8227 - 8234
12345